

## Special Issue

# Recent Advances in Understanding and Treating Amyloidosis

### Message from the Guest Editor

Amyloidosis is a hallmark of several neurodegenerative disorders (NDs) that afflict large numbers of the world's population. To date, approximately 50 distinct human pathologies, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), have been related to the accumulation of amyloid deposits that consist of ordered protein assemblies formed by a specific peptide or protein.

Amyloid- $\beta$ ,  $\alpha$ -synuclein, and transactive response DNA-binding protein 43 (TDP43), which are involved in AD, PD, and ALS, possess metal-binding sites that have been linked to their neurotoxicity. The binding with metal ions triggers the formation of toxic oligomers and aggregates but, often, also the production of reactive oxygen species.

This Special Issue aims to highlight recent advances in our understanding of the toxic mechanisms involved in NDs and new therapeutic opportunities to modulate self- and metal-induced amyloid aggregation and toxicity.

We welcome original research papers, review articles, and short communications on recent advances and emerging concepts in amyloid-related research.

---

### Guest Editor


Dr. Valentina Oliveri

Department of Chemistry, Università degli Studi di Catania, Catania, Italy

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/56934](https://mdpi.com/si/56934)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).